Clinical trial
A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)
NCT00092547 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00092547 |
|---|---|
| Title | A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) |
| Official title | A Safety and Immunogenicity Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Preadolescents and Adolescents (Base Study). A Long Term Immunogenicity, Safety, and Effectiveness Study of GARDASIL (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine)… |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Human, Papillomavirus Infections |
| Intervention type | Biological |
| Interventions | V501, Comparator: Placebo |
| Enrollment | 1,781 |
| Start date | Oct 8, 2003 |
| Primary completion | Nov 3, 2005 |
| Completion | Jun 1, 2015 |
| First posted | Sep 28, 2004 |
| Last update posted | Feb 20, 2018 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: